As men age their natural production of testosterone can decrease resulting in symptomatic andropause. This is usually treated with testosterone replacement therapy. This therapy can give good effects, but also can produce adverse effects, partially from testosterone converting to estrogen thereby increases the man’s estrogen levels. By combining the usual testosterone with an aromatase inhibitor, like chrysin, this conversion can be stopped or reduced so the risks of prostate cancer and blood clots that usually accompany testosterone therapy can be reduced.

Treatment of patients with andropause
https://www.ncbi.nlm.nih.gov/pubmed?term=22400186

Male hormone replacement therapy including “andropause”.
https://www.ncbi.nlm.nih.gov/pubmed?term=9922917

Chrysin, a natural flavonoid enhances steroidogenesis and steroidogenic acute regulatory protein gene expression in mouse Leydig cells
https://www.ncbi.nlm.nih.gov/pubmed?term=18434361

Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors.
https://www.ncbi.nlm.nih.gov/pubmed?term=21366040

Hormone replacement therapy in women to help with menopause symptoms has become very common, but concerns about health risks of these supplements currently on the market have created a need for alternatives. An example of these risks is the elevated incidence of venous thrombosis with the use of conjugated equine estrogen (found in Premarin). The use of bioidentical hormones is a safer alternative to products like this and has shown better results than marketed estrogen supplements.

Bioidentical hormone therapy.
https://www.ncbi.nlm.nih.gov/pubmed?term=21531972

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
https://www.ncbi.nlm.nih.gov/pubmed?term=15467060

Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study.
https://www.ncbi.nlm.nih.gov/pubmed?term=21651797